These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 27896521)

  • 41. [Effects of acupuncture on PI3K/Akt/mTOR signaling pathway in rats with premature ovarian failure].
    Zhang Y; Yu B; Chen J; Zhao Z; Wang Jiali ; Huang F; Lin Y; Wang M; Zhang Y; Wei B
    Zhongguo Zhen Jiu; 2015 Jan; 35(1):53-8. PubMed ID: 25906570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
    Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
    Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
    Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
    Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
    Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting endocrine resistance: is there a role for mTOR inhibition?
    Sheri A; Martin LA; Johnston S
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benzo[b]furan derivatives induces apoptosis by targeting the PI3K/Akt/mTOR signaling pathway in human breast cancer cells.
    Kamal A; Lakshma Nayak V; Nagesh N; Vishnuvardhan MV; Subba Reddy NV
    Bioorg Chem; 2016 Jun; 66():124-31. PubMed ID: 27149364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis.
    Chen J; Crawford R; Xiao Y
    J Cell Biochem; 2013 Feb; 114(2):245-9. PubMed ID: 22930581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer.
    Rahmani F; Ferns GA; Talebian S; Nourbakhsh M; Avan A; Shahidsales S
    Gene; 2020 May; 737():144459. PubMed ID: 32045660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
    Mayer IA
    Curr Breast Cancer Rep; 2015 Dec; 7(4):210-214. PubMed ID: 26881050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
    Baselga J
    Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
    Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of buparlisib in treating breast cancer.
    Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
    Expert Opin Pharmacother; 2017 Dec; 18(18):2007-2016. PubMed ID: 29169282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis.
    McAuliffe PF; Meric-Bernstam F; Mills GB; Gonzalez-Angulo AM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S59-65. PubMed ID: 21115423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PI3K-AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds.
    Yuan Y; Long H; Zhou Z; Fu Y; Jiang B
    Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671478
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New advances in targeted therapy for breast cancer].
    Zhao J; Wu N; Zhang SC; Zhao ZW; Li LJ; Liu JT
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):353-361. PubMed ID: 32482023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HCMV modulation of cellular PI3K/AKT/mTOR signaling: New opportunities for therapeutic intervention?
    Altman AM; Mahmud J; Nikolovska-Coleska Z; Chan G
    Antiviral Res; 2019 Mar; 163():82-90. PubMed ID: 30668978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular perspective on targeted therapy in breast cancer: a review of current status.
    Demir Cetinkaya B; Biray Avci C
    Med Oncol; 2022 Jul; 39(10):149. PubMed ID: 35834030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-associated macrophages increase COX-2 expression promoting endocrine resistance in breast cancer via the PI3K/Akt/mTOR pathway.
    Qin Q; Ji H; Li D; Zhang H; Zhang Z; Zhang Q
    Neoplasma; 2021 Sep; 68(5):938-946. PubMed ID: 34619972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
    West KA; Castillo SS; Dennis PA
    Drug Resist Updat; 2002 Dec; 5(6):234-48. PubMed ID: 12531180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.